This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …

This is the sixth special report that the European Society for Blood and Marrow
Transplantation regularly publishes on the current practice and indications for …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult-to-
treat population, where no standard therapy exists. We evaluated outcomes in patients with …

As the survival of patients with mantle cell lymphoma (MCL) continues to improve, patients
are increasingly being treated with multiple regimens. However, outcome after each line …

This Guideline was compiled according to the BSH process at https://bs-41 h. org.
uk/media/16732/bsh-guidance-development-process-dec-5-18. pdf and 42 represents best …

Abstract Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are
accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen …

The aim of this retrospective study was to investigate the safety and efficacy of allogeneic
hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible …

The enrichment of viable cells is an essential step to obtain effective products for cell
therapy. While procedures exist to characterize the viability of cells, most methods to exclude …

Ibrutinib has demonstrated significant activity in relapsed/refractory mantle cell lymphoma
(MCL) in clinical trials. However, the impact of hematopoietic cell transplantation on the …